Apparently the United States’ “Responsibility to Protect” poor innocent people wherever they may live is limited to bombing and occupying their countries. Sacrificing some of the pharmaceutical industry’s billions of dollars in profits so that poor innocent people wherever they may live may . . . live? Ha!
[G]eneric drug companies say they are on the verge of selling cheaper copies of such huge sellers as Herceptin for breast cancer, Avastin for colon cancer, Rituxan for non-Hodgkin’s lymphoma and Enbrel for rheumatoid arthritis. Their entry into the market in the next year — made possible by hundreds of millions of dollars invested in biotechnology plants — could not only transform the care of patients in much of the world but also ignite a counterattack by major pharmaceutical companies and diplomats from richer countries.
Already, the Obama administration has been trying to stop an effort by poorer nations to strike a new international bargain that would allow them to get around patent rights and import cheaper Indian and Chinese knock-off drugs for cancer and other diseases, as they did to fight AIDS. The debate turns on whether diseases like cancer can be characterized as emergencies, or “epidemics.”
Rich nations and the pharmaceutical industry agreed 10 years ago to give up patent rights and the profits that come with them in the face of an AIDS pandemic that threatened to depopulate much of Africa, but they see deaths from cancer, diabetes and other noncommunicable diseases as less of an emergency and, in some cases, the inevitable consequence of better and longer living.
The inevitable consequence of putting patents and the monopoly profits they secure politically influential pharmaceutical companies over the interests of cancer-stricken patients is that many people will die preventable deaths. And Ronald Reagan’s generic knockoff is cool with that. But hey, we all gotta go some time. It’s inevitable, ya know